Consort Randomized Clinical Trial Does Liposomal Bupivacaine ( Exparel ) Significantly Reduce Postoperative Pain / Numbness in Symptomatic Teeth with a Diagnosis of Necrosis ? A Prospective , Randomized , Double-blind Trial

Although the use of liposomal bupivacaine (Exparel) did not result in a statistically significant increase in postoperative success when compared with bupivacaine, further research is indicated to evaluate this new drug for effectiveness in endodontics. Introduction: Medical studies have shown some potential for infiltrations of liposomal bupivacaine (Exparel; Pacira Pharmaceuticals, San Diego, CA), a slow-release bupivacaine solution, to extend postoperative benefits of numbness/pain relief for up to several days. Because the Food and Drug Administration has approved Exparel only for infiltrations, we wanted to evaluate if it would be effective as an infiltration to control postoperative pain. The purpose of this study was to compare an infiltration of bupivacaine with liposomal bupivacaine for postoperative numbness and pain in symptomatic patients diagnosed with pulpal necrosis experiencing moderate to severe preoperative pain. Methods: One hundred patients randomly received a 4.0-mL buccal infiltration of either bupivacaine or liposomal bupivacaine after endodontic debridement. For postoperative pain, patients were given ibuprofen/acetaminophen, and they could receive narcotic pain medication as an escape. Patients recorded their level of numbness, pain, and medication use the night of the appointment and over the next 5 days. Success was defined as no or mild postoperative pain and no narcotic use. Results: The success rate was 29% for the liposomal group and 22% for the bupivacaine group, with no significant difference (P = .4684) between the groups. Liposomal bupivacaine had some effect on soft tissue numbness, pain, and use of non-narcotic medications, but it was not clinically significant. There was no significant difference in the need for escape medication. Conclusions: For symptomatic patients diagnosed with pulpal necrosis experiencing moderate to severe preoperative pain, a 4.0-mL infiltration of liposomal bupivacaine did not result in a statistically significant increase in postoperative success compared with an infiltration of 4.0 mL bupivacaine. (J Endod 2016;-:1–6)

[1]  A. Reader,et al.  What is the Effect of No Endodontic Debridement on Postoperative Pain for Symptomatic Teeth with Pulpal Necrosis? , 2016, Journal of endodontics.

[2]  G. Murphy,et al.  Postoperative Pain and Length of Stay Lowered by Use of Exparel in Immediate, Implant-Based Breast Reconstruction , 2015, Plastic and reconstructive surgery. Global open.

[3]  J. Surdam,et al.  The use of exparel (liposomal bupivacaine) to manage postoperative pain in unilateral total knee arthroplasty patients. , 2015, The Journal of arthroplasty.

[4]  D. Man.  The Incorporation of Liposome Bupivacaine into an Opioid-Sparing Strategy for Patients Undergoing Rhytidectomy , 2014 .

[5]  B. Domb,et al.  The effect of liposomal bupivacaine injection during total hip arthroplasty: a controlled cohort study , 2014, BMC Musculoskeletal Disorders.

[6]  R. Meneghini,et al.  Liposomal bupivacaine versus traditional periarticular injection for pain control after total knee arthroplasty. , 2014, The Journal of arthroplasty.

[7]  Aaron B. Skolnik,et al.  New formulations of bupivacaine for the treatment of postoperative pain: liposomal bupivacaine and SABER-Bupivacaine , 2014, Expert opinion on pharmacotherapy.

[8]  K. Candiotti,et al.  Liposome bupivacaine for improvement in economic outcomes and opioid burden in GI surgery: IMPROVE Study pooled analysis , 2014, Journal of pain research.

[9]  S. Bergese,et al.  Liposome Bupivacaine for Postsurgical Analgesia in Adult Patients Undergoing Laparoscopic Colectomy: Results from Prospective Phase IV Sequential Cohort Studies Assessing Health Economic Outcomes☆ , 2013, Current therapeutic research, clinical and experimental.

[10]  J. G. Bonnin,et al.  ARTHROPLASTY , 1956, Der Orthopade.

[11]  C. Patronella,et al.  Use of abdominal field block injections with liposomal bupivicaine to control postoperative pain after abdominoplasty. , 2013, Aesthetic surgery journal.

[12]  J. Vogel.  Liposome bupivacaine (EXPAREL®) for extended pain relief in patients undergoing ileostomy reversal at a single institution with a fast-track discharge protocol: an IMPROVE Phase IV health economics trial , 2013, Journal of pain research.

[13]  V. Nfonsam,et al.  An extended paIn relief trial utilizing the infiltration of a long-acting Multivesicular liPosome foRmulation Of bupiVacaine, EXPAREL (IMPROVE): a Phase IV health economic trial in adult patients undergoing ileostomy reversal , 2013, Journal of pain research.

[14]  E. Viscusi,et al.  A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. , 2012, The Knee.

[15]  P. White,et al.  A Double-Blind, Randomized, Active-Controlled Study for Post-Hemorrhoidectomy Pain Management with Liposome Bupivacaine, a Novel Local Analgesic Formulation , 2012, The American surgeon.

[16]  N. Ruparel.  Successful Local Anesthesia for Restorative Dentistry and Endodontics , 2012 .

[17]  H. Minkowitz,et al.  A two-year observational study assessing the safety of DepoFoam bupivacaine after augmentation mammaplasty. , 2012, Aesthetic surgery journal.

[18]  S. Bergese,et al.  The efficacy and safety of DepoFoam bupivacaine in patients undergoing bilateral, cosmetic, submuscular augmentation mammaplasty: a randomized, double-blind, active-control study. , 2012, Aesthetic surgery journal.

[19]  A. Reader,et al.  Efficacy of Ibuprofen and ibuprofen/acetaminophen on postoperative pain in symptomatic patients with a pulpal diagnosis of necrosis. , 2011, Journal of endodontics.

[20]  E. Onel,et al.  Bupivacaine Extended-Release Liposome Injection for Prolonged Postsurgical Analgesia in Patients Undergoing Hemorrhoidectomy: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial , 2011, Diseases of the colon and rectum.

[21]  S. Daniels,et al.  A phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy , 2011, Advances in therapy.

[22]  A. Reader,et al.  Effect of drainage upon access on postoperative endodontic pain and swelling in symptomatic necrotic teeth. , 2002, Journal of endodontics.

[23]  M. Henry,et al.  Effect of penicillin on postoperative endodontic pain and swelling in symptomatic necrotic teeth. , 2001, Journal of endodontics.

[24]  A. Reader,et al.  Effect of trephination on postoperative pain and swelling in symptomatic necrotic teeth. , 2000, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[25]  G. Bouloux,et al.  Bupivacaine versus lidocaine for third molar surgery: a double-blind, randomized, crossover study. , 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[26]  J. Neal,et al.  Analysis of the analgesic efficacy and cost-effective use of long-acting local anesthetics in outpatient third molar surgery. , 1993, Oral surgery, oral medicine, and oral pathology.

[27]  R. Crout,et al.  A clinical trial of long-acting local anesthetics for periodontal surgery. , 1990, Anesthesia progress.

[28]  J. R. Tuffin,et al.  Do local analgesics injected at the time of third molar removal under general anaesthesia reduce significantly post operative analgesic requirements? A double-blind controlled trial. , 1989, The British journal of oral & maxillofacial surgery.

[29]  E. Hazrati,et al.  Long-acting local anesthetics in oral surgery , 1988 .

[30]  S. Parker,et al.  An experimental basis for revising the graphic rating scale for pain , 1984, Pain.

[31]  N. L. Corah,et al.  Development of a Dental Anxiety Scale , 1969, Journal of dental research.